Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Receives $55.50 Average Price Target from Analysts

Shares of Tvardi Therapeutics, Inc. (NASDAQ:TVRD) have received an average recommendation of “Hold” from the seven analysts that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and three have given a buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $55.50.

Several research analysts have commented on TVRD shares. Barclays set a $5.00 price objective on Tvardi Therapeutics and gave the company an “equal weight” rating in a research report on Monday, October 13th. Cantor Fitzgerald lowered Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, October 13th. Piper Sandler cut Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday, October 13th. Wall Street Zen upgraded shares of Tvardi Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, January 6th. Finally, Weiss Ratings restated a “sell (e)” rating on shares of Tvardi Therapeutics in a research note on Monday, December 29th.

Tvardi Therapeutics Stock Performance

NASDAQ TVRD opened at $4.56 on Friday. Tvardi Therapeutics has a one year low of $3.74 and a one year high of $43.65. The company’s 50 day moving average price is $4.12 and its 200 day moving average price is $17.73. The firm has a market capitalization of $42.77 million, a price-to-earnings ratio of -0.47 and a beta of 0.09.

Tvardi Therapeutics (NASDAQ:TVRD) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.83) by $0.24.

Institutional Trading of Tvardi Therapeutics

Large investors have recently modified their holdings of the business. JPMorgan Chase & Co. acquired a new position in shares of Tvardi Therapeutics in the second quarter worth about $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Tvardi Therapeutics during the 2nd quarter worth approximately $43,000. Headlands Technologies LLC acquired a new position in shares of Tvardi Therapeutics in the 2nd quarter valued at approximately $80,000. New York State Common Retirement Fund purchased a new position in shares of Tvardi Therapeutics during the 2nd quarter valued at approximately $92,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of Tvardi Therapeutics during the third quarter worth approximately $318,000. 44.66% of the stock is currently owned by institutional investors and hedge funds.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.